Results 91 to 100 of about 8,788 (204)

Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.

PLoS ONE
Nirmatrelvir/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety.
Ji Sun, Xuanyu Deng, Juanjuan Huang, Gefei He, Shiqiong Huang   +4 more
doaj   +1 more source

Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective

Drugs - Real World Outcomes
Background and objectives Nirmatrelvir/ritonavir was administered orally to manage mild to moderate symptoms of COVID-19 in adult patients. The objectives of this study were to (i) evaluate the cost-effectiveness of prescribing nirmatrelvir/ritonavir ...
Ee Vien Low, Hoon Shien Teh, Nicholas Yee Liang Hing, Suresh Kumar Chidambaram, Mohan Dass Pathmanathan, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +14 more
doaj   +1 more source

A Case Report of Severe Bradycardia Associated With Nirmatrelvir-ritonavir Drug-drug Interactions

Cardiology Discovery
. With the increasing use of nirmatrelvir-ritonavir in older COVID-19 patients, adverse drug reactions due to drug-drug interactions have become more frequent.
Zhiqing Fu, Yan Guo, Shuai Li, Yang Shi, Hanjia Gao   +4 more
doaj   +1 more source

Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series [PDF]

, 2023
Bonora, Stefano, Calcagno, Andrea, De Rosa, Francesco Giuseppe, Frascione, Pio Manlio Mirko, Pepe, Andrea, Ponzetta, Laura, Ranzani, Fabio Antonino, Vita, Davide   +7 more
core   +1 more source

Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: A single‐center large observational study

Immunity, Inflammation and Disease
Background Since coronavirus 2019 (COVID‐19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir–ritonavir is highly recommended.
Can Chen, Ranyi Li, Shuliang Xing, Lei Cao, Yue Qu, Qianzhou Lv, Xiaoyu Li, Zhangzhang Chen   +7 more
doaj   +1 more source

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19

Microbiology Spectrum
Immunocompromised individuals are susceptible to severe coronavirus disease 2019 and potentially contribute to the emergence of variants with altered pathogenicity due to persistent infection.
Rebekah Penrice-Randal, Eleanor G. Bentley, Parul Sharma, Adam Kirby, I'ah Donovan-Banfield, Anja Kipar, Daniele F. Mega, Chloe Bramwell, Joanne Sharp, Andrew Owen, Julian A. Hiscox, James P. Stewart   +11 more
doaj   +1 more source

Properties of Algerian Medicinal Thyme Compounds: Simulation using SwissADME and SuperPred Servers for the in Silico Study of Pharmacokinetic Parameters and Bioactivity. [PDF]

A large number of medicinal plants are used for the curative and preventive treatment of many diseases. In this article, we are interested in the study of the biological properties of Algerian medicinal thyme compounds using in-silico approaches.
CHEGHIB, Nedjoua, DJAHOUDI , Abdelghani, LAREDJ, Hacene, MECHACHTI , Manar, SOUDANI , Wafa, ZEROUAL , Nada Insaf   +5 more
core   +1 more source

Selective Inhibition of Vascular Smooth Muscle Cell Function by COVID-19 Antiviral Drugs: Impact of Heme Oxygenase-1

Antioxidants
Coronavirus disease 2019 (COVID-19) causes cardiovascular complications, which contributes to the high mortality rate of the disease. Emerging evidence indicates that aberrant vascular smooth muscle cell (SMC) function is a key driver of vascular disease
Kelly J. Peyton, Giovanna L. Durante, William Durante   +2 more
doaj   +1 more source

IPNA clinical practice recommendations on care of pediatric patients with pre-existing kidney disease during seasonal outbreak of COVID-19 [PDF]

The coronavirus disease 2019 (COVID-19) pandemic, instigated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has profoundly impacted healthcare infrastructures around the globe.
Admani B., Alhasan K. A., Allen U., Amer Y. S., Ashoor I. F., Bagga A., Bhimma R., Bonilla-Felix M., Boyer O., Bresolin N. L., Coccia P., Dharnidharka V., Duzova A., Esezobor C., Exantus J., Filler G., Haffner D., Hari P., Khan S. A., Koch V., Koh J., Ma A., Mantan M., Marlais M., McCulloch M., Montini G., Morello W., Prestidge C., Raina R., Restrepo J. M., Rodriguez L. I., Safouh H., Sethi S. K., Smith J. M., Temsah M. -H., Trnka P., Vasudevan A., Zhong X.   +37 more
core   +1 more source

Efficient in vitro assay for evaluating drug efficacy and synergy against emerging SARS-CoV-2 strains [PDF]

Novel and repurposed antiviral drugs are available for the treatment of coronavirus disease 2019 (COVID-19). However, antiviral combinations may be more potent and lead to faster viral clearance, but the methods for screening antiviral combinations ...
Agyeman, Akosua Adom, Breuer, Judith, Buggiotti, Laura, Ellis, Samuel, Jacobs, Amy I, Kembou-Ringert, Japhette, Kite, Kerry-Anne, Masonou, Tereza, Mchugh, Timothy D, Palor, Machaela, Smith, Claire M, Standing, Joseph F, Woodall, Maximillian, Zhang, Shengyuan   +13 more
core